financetom
Business
financetom
/
Business
/
ConocoPhillips Q1 Beat Driven by Higher Production, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ConocoPhillips Q1 Beat Driven by Higher Production, UBS Says
May 26, 2025 5:21 AM

02:50 PM EDT, 05/09/2025 (MT Newswires) -- ConocoPhillips' ( COP ) better-than-expected Q1 earnings were mainly driven by stronger-than-forecast production volumes, UBS Securities said.

The company reported adjusted Q1 earnings of $2.09 per diluted share, above UBS and Street estimates of $2.06 and $2.05, respectively. UBS attributed the beat primarily to production, which came in at 2.389 million barrels of oil equivalent per day, above both UBS and consensus expectations, and the high end of company guidance.

While cash flow per share missed forecasts due to deferred tax headwinds, operating costs came in below expectations. Q1 capital expenditures were also lower than forecast, totaling $3.4 billion versus UBS's estimate of $3.6 billion.

Despite $1.3 billion in non-core asset sales and a $450 million cut to full-year capital spending guidance, ConocoPhillips ( COP ) maintained its 2025 production target of 2.34 to 2.38 million boepd. UBS said this reflects improved operational efficiency and cited ongoing progress on the integration of Marathon Oil and related cost synergies.

Capital returns in Q1 totaled $2.5 billion, including $1.5 billion in share repurchases, slightly below UBS's $1.6 billion buyback estimate. UBS views the update as positive overall, highlighting the company's diversified asset base, cost discipline, and long-cycle growth potential from projects like Willow and LNG.

UBS has a buy rating and $111 price target on the stock.

Price: 88.97, Change: +0.15, Percent Change: +0.16

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Helmerich & Payne to Acquire Drilling Firm KCA Deutag For $1.97 Billion; Shares Rise
Update: Helmerich & Payne to Acquire Drilling Firm KCA Deutag For $1.97 Billion; Shares Rise
Jul 25, 2024
12:46 PM EDT, 07/25/2024 (MT Newswires) -- (Updates with share price movement, adds Q3 results) Helmerich & Payne (HP) shares were up about 10% in recent Thursday trading after the company struck a deal to acquire drilling firm KCA Deutag International and reported better-than-expected fiscal Q3 results. Earlier, the firm said it would acquire KCA Deutag for $1.97 billion in...
US sour crude Mars values hit 9-month low on weaker refinery demand
US sour crude Mars values hit 9-month low on weaker refinery demand
Jul 25, 2024
HOUSTON, July 25 (Reuters) - Differentials for U.S. sour crude Mars have been in a steep decline this month and hit their widest discount to benchmark crude futures since October this week, according to data from brokers, as refiners faced slimmer profit margins due to weak demand. The offshore crude grade's discount to West Texas Intermediate crude (WTI) at the...
Embraer opens P&W repair hub as demand for engine maintenance rockets
Embraer opens P&W repair hub as demand for engine maintenance rockets
Jul 25, 2024
SAO PAULO (Reuters) - Brazilian planemaker Embraer ( ERJ ) on Thursday opened a maintenance hub for Pratt & Whitney (P&W) engines in Portugal, which it expects to bring in an additional 600 million euros ($653 million) in revenues per year once fully operational. The move comes amid surging demand for aircraft maintenance as airlines and manufacturers struggle with supply...
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Jul 25, 2024
Eli Lilly and Company ( LLY ) stock is trading lower on Thursday after Viking Therapeutics, Inc. ( VKTX ) announced the advancement of its novel treatment for obesity, VK2735. The Details: Viking is advancing the injectable form of VK2735 to Phase 3 after receiving written feedback from an FDA Type C meeting. Also, the Phase 2 venture study of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved